From: Use of continuous glucose monitoring in insulin-treated older adults with type 2 diabetes
n (%) | |
---|---|
Oral Antidiabetic Drugs (OAD) | |
SGLT2i | 15 (22.7%) |
Sulfonylureas | 42 (63.6%) |
DPP-4i | 11 (16.7%) |
TZDs | 0 (0.0%) |
Metformin | 52 (78.8%) |
No OAD | 8 (12.1%) |
Insulin Regimens + OAD | 82.1% |
NPH | 38 (57.6%) |
NPH + Regular | 14 (21,2%) |
Degludeca | 1 (1.5%) |
Degludeca + Rapid Analog | 1 (1.5%) |
Glargine | 5 (7.6%) |
Glargine + Rapid Analog | 7 (10.6%) |
Premix | 0 (0,0%) |